CXCR4 antagonists suppress small cell lung cancer progression
PDF | HTML | How to cite
Metrics: PDF 1838 views | HTML 2362 views | ?
Sanaz Taromi1, Gian Kayser2, Julie Catusse1, Dominik von Elverfeldt3, Wilfried Reichardt3, Friederike Braun4,5,6, Wolfgang A. Weber4,5, Robert Zeiser1, Meike Burger1,7
1Department of Medicine, Division of Hematology/Oncology, University Medical Center, Hugstetter, D-79106 Freiburg, Germany
2Department of Pathology, University Medical Center, Breisacher, D-79106 Freiburg
3Department of Radiology Medical Physics, University Medical Center, Breisacher, D-79106 Freiburg
4Institute of Nuclear Medicine, University Medical Center, Hugstetter D-79106 Freiburg, Germany
5Department of Radiology, Memorial Sloan Kettering Cancer Center, New York 10065, NY, USA
6University of Freiburg, Faculty of Biology, Schaenzlestrasse, D-79106 Freiburg, Germany
7University Furtwangen, Faculty of Medical and Life Sciences, Campus Schwenningen, VS-78054 Schwenningen, Germany
Meike Burger, email: [email protected], [email protected]
Keywords: small cell lung cancer, metastasis, mouse model, CXCL12, AMD3100
Acronyms: Bioluminescence Imaging (BLI), Magnetic Resonance Imaging (MRI), Positron emission tomography (PET), Small Cell Lung Cancer (SCLC).
Received: July 25, 2016 Accepted: October 27, 2016 Published: November 09, 2016
Small cell lung cancer (SCLC) is an aggressive tumor with poor prognosis due to early metastatic spread and development of chemoresistance. Playing a key role in tumor-stroma interactions the CXCL12-CXCR4 axis may be involved in both processes and thus represent a promising therapeutic target in SCLC treatment. In this study we investigated the effect of CXCR4 inhibition on metastasis formation and chemoresistance using an orthotopic xenograft mouse model. This model demonstrates regional spread and spontaneous distant metastases closely reflecting the clinical situation in extensive SCLC. Tumor engraftment, growth, metabolism, and metastatic spread were monitored using different imaging techniques: Magnetic Resonance Imaging (MRI), Bioluminescence Imaging (BLI) and Positron Emission Tomography (PET). Treatment of mice bearing chemoresistant primary tumors with the specific CXCR4 inhibitor AMD3100 reduced the growth of the primary tumor by 61% (P<0.05) and additionally suppressed metastasis formation by 43%. In comparison to CXCR4 inhibition as a monotherapy, standard chemotherapy composed of cisplatin and etoposide reduced the growth of the primary tumor by 71% (P<0.01) but completely failed to suppress metastasis formation. Combination of chemotherapy and the CXCR4 inhibitor integrated the highest of both effects. The growth of the primary tumor was reduced to a similar extent as with chemotherapy alone and metastasis formation was reduced to a similar extent as with CXCR4 inhibitor alone. In conclusion, we demonstrate in this orthotopic mouse model that the addition of a CXCR4 inhibitor to chemotherapy significantly reduces metastasis formation. Thus, it might improve the overall therapy response and consequently the outcome of SCLC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.